GBA1 and Parkinson disease: ABX is currently studied (also IIRs) as a PC therapy for patients with GBA1-related and idiopathic PD [22], and in GBA1-related dementia [25]; it will soon be studied for the prevention of GBA1-related PD in individuals with advanced prodromal features [26,27].